134 related articles for article (PubMed ID: 16946524)
1. Effect of glimepiride and glibenclamide on S-warfarin 7-hydroxylation by human liver microsomes, recombinant human CYP2C9.1 and CYP2C9.3.
Iwakawa S; Miyashita K; Hashimoto Y; Kuroda T
Biol Pharm Bull; 2006 Sep; 29(9):1983-5. PubMed ID: 16946524
[TBL] [Abstract][Full Text] [Related]
2. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
Yamazaki H; Inoue K; Shimada T
Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
[TBL] [Abstract][Full Text] [Related]
3. Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro.
Chen SZ; Pan PP; Shen LB; Xu SS; Dai DP; Geng PW; Cai J; Cai JP; Hu GX
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):732-8. PubMed ID: 24986093
[TBL] [Abstract][Full Text] [Related]
4. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
Yamazaki H; Shimada T
Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
[TBL] [Abstract][Full Text] [Related]
5. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.
Jones DR; Kim SY; Guderyon M; Yun CH; Moran JH; Miller GP
Chem Res Toxicol; 2010 May; 23(5):939-45. PubMed ID: 20429590
[TBL] [Abstract][Full Text] [Related]
6. Effect of ethanol on S-warfarin and diclofenac metabolism by recombinant human CYP2C9.1.
Tatsumi A; Ikegami Y; Morii R; Sugiyama M; Kadobayashi M; Iwakawa S
Biol Pharm Bull; 2009 Mar; 32(3):517-9. PubMed ID: 19252308
[TBL] [Abstract][Full Text] [Related]
7. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of sesamin on CYP2C9-dependent 7-hydroxylation of S-warfarin.
Fujii M; Yasuda K; Sakaki T
Drug Metab Pharmacokinet; 2020 Aug; 35(4):368-373. PubMed ID: 32601017
[TBL] [Abstract][Full Text] [Related]
9. Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.
Zhang N; Seguin RP; Kunze KL; Zhang YY; Jeong H
Drug Metab Dispos; 2013 Dec; 41(12):2114-23. PubMed ID: 24046330
[TBL] [Abstract][Full Text] [Related]
10. Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation.
Zhang ZY; Kerr J; Wexler RS; Li HY; Robinson AJ; Harlow PP; Kaminsky LS
Thromb Res; 1997 Nov; 88(4):389-98. PubMed ID: 9526963
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.
Hemeryck A; De Vriendt C; Belpaire FM
Eur J Clin Pharmacol; 1999 Feb; 54(12):947-51. PubMed ID: 10192756
[TBL] [Abstract][Full Text] [Related]
12. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.
Rettie AE; Korzekwa KR; Kunze KL; Lawrence RF; Eddy AC; Aoyama T; Gelboin HV; Gonzalez FJ; Trager WF
Chem Res Toxicol; 1992; 5(1):54-9. PubMed ID: 1581537
[TBL] [Abstract][Full Text] [Related]
13. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase.
Sandberg M; Yasar U; Strömberg P; Höög JO; Eliasson E
Br J Clin Pharmacol; 2002 Oct; 54(4):423-9. PubMed ID: 12392591
[TBL] [Abstract][Full Text] [Related]
14. In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride.
Dai DP; Wang SH; Geng PW; Hu GX; Cai JP
Basic Clin Pharmacol Toxicol; 2014 Apr; 114(4):305-10. PubMed ID: 24118918
[TBL] [Abstract][Full Text] [Related]
15. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.
Yamaori S; Koeda K; Kushihara M; Hada Y; Yamamoto I; Watanabe K
Drug Metab Pharmacokinet; 2012; 27(3):294-300. PubMed ID: 22166891
[TBL] [Abstract][Full Text] [Related]
16. R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
Yong WP; Kim TW; Undevia SD; Innocenti F; Ratain MJ
Eur J Cancer; 2009 Jul; 45(11):1904-8. PubMed ID: 19464879
[TBL] [Abstract][Full Text] [Related]
17. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.
Wienkers LC; Wurden CJ; Storch E; Kunze KL; Rettie AE; Trager WF
Drug Metab Dispos; 1996 May; 24(5):610-4. PubMed ID: 8723744
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.
Ufer M; Kammerer B; Kahlich R; Kirchheiner J; Yasar U; Brockmöller J; Rane A
Xenobiotica; 2004 Sep; 34(9):847-59. PubMed ID: 15742978
[TBL] [Abstract][Full Text] [Related]
19. In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod: possible mechanism of iguratimod-warfarin interaction.
Yamaori S; Takami K; Shiozawa A; Sakuyama K; Matsuzawa N; Ohmori S
Biol Pharm Bull; 2015; 38(3):441-7. PubMed ID: 25757926
[TBL] [Abstract][Full Text] [Related]
20. Effects of acid and lactone forms of statins on S-warfarin 7-hydroxylation catalyzed by human liver microsomes and recombinant CYP2C9 variants (CYP2C9.1 and CYP2C9.3).
Shiozawa A; Yamaori S; Kamijo S; Ohmori S
Drug Metab Pharmacokinet; 2021 Feb; 36():100364. PubMed ID: 33341662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
